Viking Therapeutics Financial Statements
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.51+0.78 (+2.81%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viking Therapeutics revenue and earnings
In fiscal 2025, Viking Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Viking Therapeutics reported a net loss of $359.6 million, compared with a loss of $110.0 million a year earlier. Diluted earnings per share came in at -$3.19.
Summary generated from market data by MetaCap's automated system. Methodology
Viking Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 393.34M | 150.92M | 100.83M | 70.36M | 55.68M | 42.66M | 32.69M | 26.16M | 19.07M | 13.85M |
| Research & Development | 344.95M | 101.64M | 63.81M | 54.23M | 44.98M | 31.93M | 23.56M | 19.04M | 13.74M | 9.00M |
| Operating Income | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M | -42.66M | -32.69M | -26.16M | -19.07M | -13.85M |
| Other Income (Expense) | 33.70M | 40.96M | 14.93M | 1.49M | 692.00K | 3.17M | 6.91M | 4.10M | -1.51M | -884.55K |
| Pretax Income | -359.64M | -109.96M | -85.89M | — | — | — | — | — | — | — |
| Income Tax | 1.00K | 1.00K | 1.00K | 1.00K | 2.00K | 0 | 0 | 0 | 0 | 0 |
| Net Income | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M | -39.49M | -25.78M | -22.06M | -20.58M | -14.73M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 | -0.38 | -0.79 | -0.90 |
| EPS (Diluted) | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 | -0.38 | -0.79 | -0.90 |
| Shares Outstanding (Basic) | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M | 72.60M | 71.96M | 57.58M | 25.98M | 16.28M |
| Shares Outstanding (Diluted) | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M | 72.60M | 71.96M | 57.58M | 25.98M | 16.28M |
This table shows 10 annual periods of Viking Therapeutics's income statement, from FY 2025 back to FY 2016, across 12 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow VKTX's reporting calendar. What is a income statement?